RMC-6236 (Unresectable or Metastatic Colorectal Cancer or Pancreatic Cancer) - Clinical Trial

or email

gi-oncology-cru@dm.duke.edu

What is the Purpose of this Study?

We are doing this study to see if an experimental drug called RMC-6236 (the study drug) is a safe and effective option for treating colorectal or pancreatic cancer when it is combined with different chemotherapy drugs.

What is the Condition Being Studied?

Metastatic or Unresectable Colorectal Cancer (CRC) or Metastatic Pancreatic Cancer

Who Can Participate in the Study?

Adults ages 18+ who:

Are diagnosed with metastatic or unresectable colorectal cancer; OR
Are diagnosed with metastatic pancreatic cancer

For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.

Age Group

Adults

What is Involved?

If you choose to join this study, you will:

Receive the study drug and chemotherapy with or without irinotecan, or with bevacizumab
Have a tumor biopsy done, if necessary
Have blood draws
Have imaging scans (CT or MRI)

Study Details

Full Title

Study of RMC-6236 in Combination with 5-flourouracil-based Regimens in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma– Subprotocol A

Principal Investigator